Pre-made Vixtimotamab benchmark antibody ( Bispecific Homodimer (VK-VH-VL'-VH', Tandem diabody), anti-CD3E;CD33 therapeutic antibody, Anti-T3E/TCRE/IMD18;p67/SIGLEC3/SIGLEC-3 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-624

Pre-Made Vixtimotamab biosimilar, Bispecific Homodimer (VK-VH-VL'-VH', Tandem diabody)), Anti-CD3E;CD33 Antibody: Anti-T3E/TCRE/IMD18;p67/SIGLEC3/SIGLEC-3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.



Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-624-1mg 1mg Inquiry
GMP-Bios-ab-624-10mg 10mg Inquiry
GMP-Bios-ab-624-100mg 100mg Inquiry
GMP-Bios-ab-624-xmg ＞100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Vixtimotamab biosimilar, Bispecific Homodimer (VK-VH-VL'-VH', Tandem diabody)), Anti-CD3E;CD33 Antibody: Anti-T3E/TCRE/IMD18;p67/SIGLEC3/SIGLEC-3 therapeutic antibody
INN Name Vixtimotamab
TargetCD3E;CD33
FormatBispecific Homodimer (VK-VH-VL'-VH', Tandem diabody)
DerivationBispecific antibody
Species ReactivityHuman
CH1 Isotypena;na
VD LCKappa;Lambda
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2020
Year Recommendedna
CompaniesAmphivena Therapeutics
Conditions Approvedna
Conditions ActiveAcute myeloid leukemia;Myelodysplastic syndromes
Conditions Discontinuedna
Development Techna